Cambridge Epigenetics

The IP stems from the work of Anjana Rao, who identified 5-hydroxymethylcytosine (5hmC) as a cancer diagnostic biomarker.

While reimbursement and regulatory issues may make some cautious, investors are encouraged by the promise of breakthrough outcomes in a variety of applications.

The company was founded as a spinout of the University of Cambridge to commercialize an epigenetic sequencing technique called oxidative bisulfite sequencing.

Lab7 Systems has released a beta version of its next-generation sequencing data workflow management software platform, available for download to early-access users from the company's website. The company is planning updates to the software every four to six weeks.

This article was originally published May 17.
Startup firm Cambridge Epigenetix plans to commercialize an epigenetic sequencing technique, with the launch of its first product — called TrueMethyl — expected in August.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.